Novartis seeks to deepen India innovation play

Swiss pharma major Novartis is sharpening its strategy in India as a pure-play innovator across core therapy segments, including cardiovascular, oncology, and immunology. The company is moving further up the value chain in India, with early scientific discovery and Phase I studies beginning to take shape.

More From Author

Loans outrun deposits, margins dip

CCI to probe Pernod Ricard, seven others

Leave a Reply